摘要
目的观察对慢性胃炎患者实施莫沙必利+艾普拉唑治疗的效果。方法选取2021年5月—2023年5月本院收治的慢性胃炎患者58例为研究对象,并按抽签分组法分为对照组和实验组,对照组采用常规治疗,实验组采用莫沙必利+艾普拉唑治疗,研究比较疗效比较、安全性、炎症反应、血清指标、复发率情况。结果评估前患者GAS、SS以及MOT、IL-6、TNF-α、PCT、CRP比较实验组与对照组无显著差异,无统计学意义(P>0.05);入组后对比后GAS、SS以及MOT、IL-6、TNF-α、PCT、CRP、疗效、安全性以及复发率对照组差于实验组,组间差异有统计学意义(P<0.05)。结论对慢性胃炎患者实施艾普拉唑+莫沙必利联合治疗后疗效显著上升,帮助患者消除炎症因子,改善患者的胃肠功能,同时有效控制疾病进展,避免疾病后期反复发作。
Objective To observe the effect of Mosapride+Ilaprazole on patients with chronic gastritis.Methods Included in the analysis of chronic gastritis patients,a total of 58 people,determine the time from May 2021 to May 2023,draw groups:control group and experimental group,the former routine treatment,while the experimental group of Mosapride+Ilaprazole treatment,study comparative efficacy,safety,inflammatory response,serum indicators,recurrence rate.Results Before evaluation,there were no significant differences in GAS,SS,MOT,IL-6,TNF-a,PCT and CRP between the experimental group and the control group,with statistical significance P>0.05;After group comparison of GAS,SS,MOT,IL-6,TNF-a,PCT,CRP,efficacy,safety and recurrence rate of the control group were worse than those of the experimental group(P<0.05).Conclusion The efficacy of Ilaprazole+Mosapride combined treatment for patients with chronic gastritis was significantly increased,which could help patients eliminate inflammatory factors and improve their gastrointestinal function.At the same time,it can effectively control the progression of the disease and avoid repeated attacks in the later stage of the disease.
作者
李伟海
LI Weihai(Chaonan District People's Hospital of Shantou,Shantou Guangdong 515144)
出处
《智慧健康》
2023年第34期58-61,共4页
Smart Healthcare
关键词
艾普拉唑
莫沙必利
慢性胃炎
炎症因子
复发率
疗效
安全性
Ilaprazole
Mosapride
Chronic gastritis
Inflammatory factors
Recurrence rate
Curative effect
Safety
